NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 182 filers reported holding NEVRO CORP in Q2 2022. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,009,600 | +0.9% | 76,000 | +18.8% | 1.53% | +39.9% |
| Q3 2022 | $2,982,000 | -23.6% | 64,000 | -28.1% | 1.09% | -30.0% |
| Q2 2022 | $3,901,000 | -30.0% | 89,000 | +15.6% | 1.56% | -16.3% |
| Q1 2022 | $5,569,000 | +63.6% | 77,000 | +83.3% | 1.86% | +98.5% |
| Q4 2021 | $3,405,000 | -42.6% | 42,000 | -17.6% | 0.94% | -39.7% |
| Q3 2021 | $5,935,000 | +33.1% | 51,000 | +89.6% | 1.56% | +50.6% |
| Q2 2021 | $4,460,000 | -15.6% | 26,900 | -29.0% | 1.03% | -29.6% |
| Q1 2021 | $5,287,000 | – | 37,900 | – | 1.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |